United Kingdom (UK) RNAI Therapeutics Market (2025-2031) | Size & Revenue, Trends, Share, Value, Segmentation, Growth, Analysis, Forecast, Industry, Competitive Landscape, Companies, Outlook

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United Kingdom (UK) Country Macro Economic Indicators

3.2 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, 2021 & 2031F

3.3 United Kingdom (UK) RNAI Therapeutics Market - Industry Life Cycle

3.4 United Kingdom (UK) RNAI Therapeutics Market - Porter's Five Forces

3.5 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F

3.6 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume Share, By End-User, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of genetic disorders and chronic diseases in the UK, creating a higher demand for RNAi therapeutics.

4.2.2 Technological advancements in RNAi technology leading to the development of more effective and targeted therapies.

4.2.3 Growing investments in research and development activities focused on RNAi therapeutics in the UK.

4.3 Market Restraints

4.3.1 Stringent regulatory requirements and approval processes for RNAi therapeutics in the UK, leading to delays in market entry.

4.3.2 High cost associated with RNAi therapy development and treatment, limiting accessibility for patients.

4.3.3 Limited awareness among healthcare professionals and patients about the benefits and applications of RNAi therapeutics.

6.1 United Kingdom (UK) RNAI Therapeutics Market, By Route of Administration

6.1.1 Overview and Analysis

6.1.2 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Route of Administration, 2021- 2031F

6.1.3 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Intradermal Injections, 2021- 2031F

6.1.4 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Pulmonary Delivery, 2021- 2031F

6.1.5 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Intravenous Injections, 2021- 2031F

6.1.6 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Intraperitoneal Injections, 2021- 2031F

6.1.7 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Others, 2021- 2031F

6.2 United Kingdom (UK) RNAI Therapeutics Market, By End-User

6.2.1 Overview and Analysis

6.2.2 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Diagnostic Laboratories, 2021- 2031F

6.2.3 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Research and Academic Laboratories, 2021- 2031F

6.2.4 United Kingdom (UK) RNAI Therapeutics Market Revenues & Volume, By Hospitals, 2021- 2031F

7.1 United Kingdom (UK) RNAI Therapeutics Market Export to Major Countries

7.2 United Kingdom (UK) RNAI Therapeutics Market Imports from Major Countries

8.1 Number of clinical trials conducted in the UK related to RNAi therapeutics.

8.2 Adoption rate of RNAi therapeutics by healthcare facilities in the UK.

8.3 Research and development funding allocated to RNAi therapy projects in the UK.

8.4 Number of partnerships and collaborations between UK-based biopharmaceutical companies and research institutions in the field of RNAi therapeutics.

8.5 Patient outcomes and improvements in disease management attributed to RNAi therapy in the UK.

9.1 United Kingdom (UK) RNAI Therapeutics Market Opportunity Assessment, By Route of Administration, 2021 & 2031F

9.2 United Kingdom (UK) RNAI Therapeutics Market Opportunity Assessment, By End-User, 2021 & 2031F

10.1 United Kingdom (UK) RNAI Therapeutics Market Revenue Share, By Companies, 2024

10.2 United Kingdom (UK) RNAI Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters